Inhibition of CDK2 kinase activity relieves granulocytic differentiation of AML cells without HSC cytotoxicity. (A) The protein levels of CDK2 and HA-CDK2 in shCDK2-transfected HL60 cells reexpressing CDK2 (CM14) or CDK2-D145N (CM14). (B-C) Differentiation analysis of shCDK2-transfected HL60 cells reexpressing CDK2 (CM14) and CDK2-D145N (CM14). (B) CD11b expression and (C) morphological changes. (D) CD11b expression in NB4, U937, HL60, and THP-1 cells treated with indicated concentrations of SU9516 for 72 hours. (E) CD11b expression in HL60 cells treated with indicated concentrations of CVT313 or Nu6102 for 72 hours. (F) Bacterial killing ability of NB4, U937, and THP-1 cells treated with indicated concentrations of SU9516 for 5 days. S aureus was used to infect AML cells. (G) Proliferation assay and (H) viability assay of HSC cells treated with SU9516 for indicated times. Cells were stained with trypan blue and counted every 2 days. (I) Bacterial killing ability of HSC cells treated with indicated concentrations of SU9516 for 7 days. S aureus was used to infect HSC. (B,D-G,I) *P < .05; **P < .01; ***P < .001 vs control or as indicated. Data are shown as mean ± SD, n = 3. Other data are representative of at least 3 individual experiments; 1 representative image is shown.